One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Osmotica Study Site-161, Plainview

Osmotica Study Site-163, Philadelphia

Osmotica Study Site-166, Vienna

Osmotica Study Site-157, High Point

Osmotica Study Site-155, Raleigh

Osmotica Study Site-151, Charlotte

Osmotica Study Site-152, Wilmington

Osmotica Study Site-178, Pompano Beach

Osmotica Study Site-170, Tampa

Osmotica Study Site-173, Bradenton

Osmotica Study Site-657, Poltava

Osmotica Study Site-162, Franklin

Osmotica Study Site-156, Dayton

Osmotica Study Site-175, Ann Arbor

Osmotica Study Site-653, Dnipropetrovsk

Osmotica Study Site-655, Dnipropetrovsk

Osmotica Study Site-179, Northbrook

Osmotica Study Site-654, Kharkiv

Osmotica Study Site-174, Lenexa

Osmotica Study Site-171, San Antonio

Osmotica Study Site-656, Lviv

Osmotica Study Site-651, Donetsk

Osmotica Study Site-158, Phoenix

Osmotica Study Site-154, Gilbert

Osmotica Study Site-164, Torrance

Osomtica Study Site-164, Torrance

Osmotica Study Site-165, Pasadena

Osmotica Study Site-557, Moscow

Osmotica Study Site-556, Moscow

Osmotica Study Site-551, Saint Petersburg

Osmotica Study Site-560, Sestroretsk

Osmotica Study Site-555, Tonnel'nyy

Osmotica Study Site-554, Krasnoyarsk

Osmotica Study Site-552, Krasnoyarsk

Osmotica Study Site-553, Pyatigorsk